Coronavirus vaccine stocks may not be the hottest stocks in the stock market today. However, the companies behind them continue to play crucial roles in the fight against Covid-19 now. By and large, this is the case as new variants continue to emerge that are boasting greater infectivity. Despite all of this, coronavirus stocks have mostly cooled off since their…
A significant number of parents who do not plan to vaccinate their 5-11-year-olds should the Pfizer vaccine be authorized in the age group threaten to further complicate the future of the pandemic. The U.S. is on the cusp of allowing about 28 million children ages 5-11 to get vaccinated against COVID-19, opening up the potential to significantly expand vaccination coverage…
While the biotech industry’s near-term potential is largely tied to the development of treatments for COVID-19, the author of today’s article notes that “The sector’s long-term potential remains solid due to the aging population and the rising cost of healthcare.” Against this backdrop, they proceed to highlight two biotech stocks that Wall Street analysts expect will see significant gains of…
Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product…
As the biotech sector has received increased investor focus over the past year amid the COVID-19 pandemic, the author of today’s article notes that “Even the smaller and lesser known are being seen now as having immense potential; Many of these companies are working tirelessly toward new drug developments and eyeing larger collaborations.” With that, she proceeds to highlight three…
“These four look like solid picks for more aggressive growth investors as they have significant catalysts that can drive growth for the rest of 2021 and beyond,” says the author of today’s article in regards to the four stocks he proceeds to highlight, each of which is a top growth stock call for 2021 from Jefferies. For these four stocks…
While the most important decisions made by the FDA in December were undoubtedly the Emergency Use Authorizations for two COVID-19 vaccines, the month also saw a number of firsts on the regulatory front, including the authorization of the first test allowing for at-home collection of patient samples to detect both COVID-19 and influenza A and B. Now, today’s article takes…
While the pharma/biotech sector was not spared COVID-19 pain this year, with various companies hit hard by disruptions in clinical studies and delays in elective surgeries and in individuals seeking medical care, the authors of today’s article note that “some biotech stocks have more than doubled during this period, especially those focusing on developing a coronavirus vaccine.” They proceed to…
Today’s article highlights “a low-risk, high-quality small biotech with high growth potential.” More specifically, this “is a revolutionary biotech company that uses tissue engineering to treat/repair sports-related injuries and severe burns” – and while it was negatively impacted this year by the canceling and delaying of elective surgeries due to COVID-19, the author outlines why rapid growth should return in…
While the small biotech company featured in today’s article is not working on solving the health problem of the day – COVID-19 – it is solving a major problem that affects one in eight couples and is more prevalent than diabetes, asthma and depression. And with the company having “a clear-cut mission, great management, and a history of revenue growth”,…